nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclopentolate—BCHE—Triamcinolone—hematologic cancer	0.193	0.421	CbGbCtD
Cyclopentolate—BCHE—Irinotecan—hematologic cancer	0.146	0.319	CbGbCtD
Cyclopentolate—BCHE—Cisplatin—hematologic cancer	0.119	0.26	CbGbCtD
Cyclopentolate—Venlafaxine—ABCG2—hematologic cancer	0.000959	0.485	CrCbGaD
Cyclopentolate—Flushing—Carmustine—hematologic cancer	0.000648	0.00142	CcSEcCtD
Cyclopentolate—Agitation—Bortezomib—hematologic cancer	0.000645	0.00141	CcSEcCtD
Cyclopentolate—Flushing—Alitretinoin—hematologic cancer	0.000642	0.00141	CcSEcCtD
Cyclopentolate—Conjunctivitis—Cisplatin—hematologic cancer	0.000638	0.0014	CcSEcCtD
Cyclopentolate—Dry mouth—Lenalidomide—hematologic cancer	0.000635	0.00139	CcSEcCtD
Cyclopentolate—Somnolence—Imatinib—hematologic cancer	0.000635	0.00139	CcSEcCtD
Cyclopentolate—Vasodilation—Doxorubicin—hematologic cancer	0.000635	0.00139	CcSEcCtD
Cyclopentolate—Vasodilation procedure—Doxorubicin—hematologic cancer	0.000635	0.00139	CcSEcCtD
Cyclopentolate—Flushing—Ifosfamide—hematologic cancer	0.000634	0.00139	CcSEcCtD
Cyclopentolate—Vertigo—Bortezomib—hematologic cancer	0.00063	0.00138	CcSEcCtD
Cyclopentolate—Psychotic disorder—Dexamethasone—hematologic cancer	0.000627	0.00138	CcSEcCtD
Cyclopentolate—Psychotic disorder—Betamethasone—hematologic cancer	0.000627	0.00138	CcSEcCtD
Cyclopentolate—Tachycardia—Melphalan—hematologic cancer	0.000625	0.00137	CcSEcCtD
Cyclopentolate—Pruritus—Teniposide—hematologic cancer	0.000624	0.00137	CcSEcCtD
Cyclopentolate—Somnolence—Cladribine—hematologic cancer	0.000624	0.00137	CcSEcCtD
Cyclopentolate—Rash—Methoxsalen—hematologic cancer	0.000622	0.00136	CcSEcCtD
Cyclopentolate—Dermatitis—Methoxsalen—hematologic cancer	0.000621	0.00136	CcSEcCtD
Cyclopentolate—Vision blurred—Thiotepa—hematologic cancer	0.000617	0.00135	CcSEcCtD
Cyclopentolate—Abdominal distension—Triamcinolone—hematologic cancer	0.000616	0.00135	CcSEcCtD
Cyclopentolate—Vertigo—Vinorelbine—hematologic cancer	0.000616	0.00135	CcSEcCtD
Cyclopentolate—Coordination abnormal—Epirubicin—hematologic cancer	0.000614	0.00135	CcSEcCtD
Cyclopentolate—Convulsion—Bortezomib—hematologic cancer	0.000608	0.00133	CcSEcCtD
Cyclopentolate—Tachycardia—Lenalidomide—hematologic cancer	0.000607	0.00133	CcSEcCtD
Cyclopentolate—Lacrimation increased—Doxorubicin—hematologic cancer	0.000605	0.00133	CcSEcCtD
Cyclopentolate—Rash—Mercaptopurine—hematologic cancer	0.000604	0.00132	CcSEcCtD
Cyclopentolate—Dermatitis—Mercaptopurine—hematologic cancer	0.000603	0.00132	CcSEcCtD
Cyclopentolate—Flushing—Irinotecan—hematologic cancer	0.000602	0.00132	CcSEcCtD
Cyclopentolate—Agitation—Thiotepa—hematologic cancer	0.000601	0.00132	CcSEcCtD
Cyclopentolate—Vision blurred—Thalidomide—hematologic cancer	0.000596	0.00131	CcSEcCtD
Cyclopentolate—Rash—Clofarabine—hematologic cancer	0.000595	0.00131	CcSEcCtD
Cyclopentolate—Rash—Daunorubicin—hematologic cancer	0.000595	0.00131	CcSEcCtD
Cyclopentolate—Dermatitis—Clofarabine—hematologic cancer	0.000595	0.0013	CcSEcCtD
Cyclopentolate—Dermatitis—Daunorubicin—hematologic cancer	0.000595	0.0013	CcSEcCtD
Cyclopentolate—Tremor—Thalidomide—hematologic cancer	0.000593	0.0013	CcSEcCtD
Cyclopentolate—Rash—Pentostatin—hematologic cancer	0.000593	0.0013	CcSEcCtD
Cyclopentolate—Rash—Anagrelide—hematologic cancer	0.000593	0.0013	CcSEcCtD
Cyclopentolate—Dermatitis—Anagrelide—hematologic cancer	0.000592	0.0013	CcSEcCtD
Cyclopentolate—Dermatitis—Pentostatin—hematologic cancer	0.000592	0.0013	CcSEcCtD
Cyclopentolate—Coma—Methotrexate—hematologic cancer	0.000588	0.00129	CcSEcCtD
Cyclopentolate—Agitation—Thalidomide—hematologic cancer	0.000582	0.00128	CcSEcCtD
Cyclopentolate—Pruritus—Busulfan—hematologic cancer	0.000578	0.00127	CcSEcCtD
Cyclopentolate—Conjunctivitis—Prednisolone—hematologic cancer	0.000577	0.00126	CcSEcCtD
Cyclopentolate—Vision blurred—Carmustine—hematologic cancer	0.000573	0.00126	CcSEcCtD
Cyclopentolate—Rash—Idarubicin—hematologic cancer	0.000572	0.00125	CcSEcCtD
Cyclopentolate—Dermatitis—Idarubicin—hematologic cancer	0.000571	0.00125	CcSEcCtD
Cyclopentolate—Tremor—Carmustine—hematologic cancer	0.000569	0.00125	CcSEcCtD
Cyclopentolate—Vertigo—Thalidomide—hematologic cancer	0.000569	0.00125	CcSEcCtD
Cyclopentolate—Coordination abnormal—Doxorubicin—hematologic cancer	0.000568	0.00125	CcSEcCtD
Cyclopentolate—Vision blurred—Alitretinoin—hematologic cancer	0.000567	0.00124	CcSEcCtD
Cyclopentolate—Convulsion—Thiotepa—hematologic cancer	0.000567	0.00124	CcSEcCtD
Cyclopentolate—Tremor—Alitretinoin—hematologic cancer	0.000564	0.00124	CcSEcCtD
Cyclopentolate—Pruritus—Procarbazine—hematologic cancer	0.000561	0.00123	CcSEcCtD
Cyclopentolate—Vision blurred—Ifosfamide—hematologic cancer	0.000561	0.00123	CcSEcCtD
Cyclopentolate—Tachycardia—Bortezomib—hematologic cancer	0.000559	0.00123	CcSEcCtD
Cyclopentolate—Agitation—Carmustine—hematologic cancer	0.000559	0.00123	CcSEcCtD
Cyclopentolate—Rash—Teniposide—hematologic cancer	0.000556	0.00122	CcSEcCtD
Cyclopentolate—Dermatitis—Teniposide—hematologic cancer	0.000556	0.00122	CcSEcCtD
Cyclopentolate—Agitation—Alitretinoin—hematologic cancer	0.000553	0.00121	CcSEcCtD
Cyclopentolate—Somnolence—Lenalidomide—hematologic cancer	0.000553	0.00121	CcSEcCtD
Cyclopentolate—Coma—Epirubicin—hematologic cancer	0.000551	0.00121	CcSEcCtD
Cyclopentolate—Pruritus—Dasatinib—hematologic cancer	0.00055	0.00121	CcSEcCtD
Cyclopentolate—Pruritus—Bexarotene—hematologic cancer	0.00055	0.00121	CcSEcCtD
Cyclopentolate—Pruritus—Fludarabine—hematologic cancer	0.000548	0.0012	CcSEcCtD
Cyclopentolate—Convulsion—Thalidomide—hematologic cancer	0.000548	0.0012	CcSEcCtD
Cyclopentolate—Flushing—Cisplatin—hematologic cancer	0.000547	0.0012	CcSEcCtD
Cyclopentolate—Agitation—Ifosfamide—hematologic cancer	0.000547	0.0012	CcSEcCtD
Cyclopentolate—Psychotic disorder—Prednisone—hematologic cancer	0.000546	0.0012	CcSEcCtD
Cyclopentolate—Tachycardia—Vinorelbine—hematologic cancer	0.000546	0.0012	CcSEcCtD
Cyclopentolate—Somnolence—Hydroxyurea—hematologic cancer	0.000546	0.0012	CcSEcCtD
Cyclopentolate—Vertigo—Ifosfamide—hematologic cancer	0.000535	0.00117	CcSEcCtD
Cyclopentolate—Agitation—Vincristine—hematologic cancer	0.000533	0.00117	CcSEcCtD
Cyclopentolate—Vision blurred—Mitoxantrone—hematologic cancer	0.000533	0.00117	CcSEcCtD
Cyclopentolate—Conjunctivitis—Triamcinolone—hematologic cancer	0.00053	0.00116	CcSEcCtD
Cyclopentolate—Dry mouth—Thalidomide—hematologic cancer	0.000527	0.00116	CcSEcCtD
Cyclopentolate—Convulsion—Carmustine—hematologic cancer	0.000527	0.00116	CcSEcCtD
Cyclopentolate—Convulsion—Alitretinoin—hematologic cancer	0.000522	0.00114	CcSEcCtD
Cyclopentolate—Vertigo—Vincristine—hematologic cancer	0.000521	0.00114	CcSEcCtD
Cyclopentolate—Tachycardia—Thiotepa—hematologic cancer	0.000521	0.00114	CcSEcCtD
Cyclopentolate—Pruritus—Chlorambucil—hematologic cancer	0.000519	0.00114	CcSEcCtD
Cyclopentolate—Convulsion—Ifosfamide—hematologic cancer	0.000516	0.00113	CcSEcCtD
Cyclopentolate—Rash—Busulfan—hematologic cancer	0.000515	0.00113	CcSEcCtD
Cyclopentolate—Dermatitis—Busulfan—hematologic cancer	0.000515	0.00113	CcSEcCtD
Cyclopentolate—Coma—Doxorubicin—hematologic cancer	0.00051	0.00112	CcSEcCtD
Cyclopentolate—Pruritus—Nilotinib—hematologic cancer	0.000508	0.00111	CcSEcCtD
Cyclopentolate—Vertigo—Irinotecan—hematologic cancer	0.000508	0.00111	CcSEcCtD
Cyclopentolate—Pruritus—Imatinib—hematologic cancer	0.000505	0.00111	CcSEcCtD
Cyclopentolate—Tachycardia—Thalidomide—hematologic cancer	0.000504	0.00111	CcSEcCtD
Cyclopentolate—Convulsion—Vincristine—hematologic cancer	0.000503	0.0011	CcSEcCtD
Cyclopentolate—Dry mouth—Alitretinoin—hematologic cancer	0.000501	0.0011	CcSEcCtD
Cyclopentolate—Flushing—Etoposide—hematologic cancer	0.000501	0.0011	CcSEcCtD
Cyclopentolate—Rash—Procarbazine—hematologic cancer	0.0005	0.0011	CcSEcCtD
Cyclopentolate—Dermatitis—Procarbazine—hematologic cancer	0.000499	0.0011	CcSEcCtD
Cyclopentolate—Pruritus—Cladribine—hematologic cancer	0.000496	0.00109	CcSEcCtD
Cyclopentolate—Rash—Dasatinib—hematologic cancer	0.00049	0.00107	CcSEcCtD
Cyclopentolate—Rash—Bexarotene—hematologic cancer	0.00049	0.00107	CcSEcCtD
Cyclopentolate—Dermatitis—Bexarotene—hematologic cancer	0.00049	0.00107	CcSEcCtD
Cyclopentolate—Dermatitis—Dasatinib—hematologic cancer	0.00049	0.00107	CcSEcCtD
Cyclopentolate—Convulsion—Mitoxantrone—hematologic cancer	0.00049	0.00107	CcSEcCtD
Cyclopentolate—Rash—Fludarabine—hematologic cancer	0.000489	0.00107	CcSEcCtD
Cyclopentolate—Dermatitis—Fludarabine—hematologic cancer	0.000488	0.00107	CcSEcCtD
Cyclopentolate—Abdominal distension—Prednisone—hematologic cancer	0.000487	0.00107	CcSEcCtD
Cyclopentolate—Tachycardia—Carmustine—hematologic cancer	0.000484	0.00106	CcSEcCtD
Cyclopentolate—Vision blurred—Cisplatin—hematologic cancer	0.000484	0.00106	CcSEcCtD
Cyclopentolate—Conjunctivitis—Dexamethasone—hematologic cancer	0.000481	0.00106	CcSEcCtD
Cyclopentolate—Conjunctivitis—Betamethasone—hematologic cancer	0.000481	0.00106	CcSEcCtD
Cyclopentolate—Tremor—Cisplatin—hematologic cancer	0.000481	0.00105	CcSEcCtD
Cyclopentolate—Tachycardia—Alitretinoin—hematologic cancer	0.00048	0.00105	CcSEcCtD
Cyclopentolate—Somnolence—Thiotepa—hematologic cancer	0.000475	0.00104	CcSEcCtD
Cyclopentolate—Somnolence—Thalidomide—hematologic cancer	0.000459	0.00101	CcSEcCtD
Cyclopentolate—Pruritus—Melphalan—hematologic cancer	0.000453	0.000993	CcSEcCtD
Cyclopentolate—Rash—Nilotinib—hematologic cancer	0.000453	0.000993	CcSEcCtD
Cyclopentolate—Dermatitis—Nilotinib—hematologic cancer	0.000452	0.000992	CcSEcCtD
Cyclopentolate—Rash—Imatinib—hematologic cancer	0.00045	0.000988	CcSEcCtD
Cyclopentolate—Tachycardia—Mitoxantrone—hematologic cancer	0.00045	0.000987	CcSEcCtD
Cyclopentolate—Dermatitis—Imatinib—hematologic cancer	0.00045	0.000987	CcSEcCtD
Cyclopentolate—Convulsion—Cisplatin—hematologic cancer	0.000445	0.000975	CcSEcCtD
Cyclopentolate—Rash—Cladribine—hematologic cancer	0.000442	0.00097	CcSEcCtD
Cyclopentolate—Hallucination—Dexamethasone—hematologic cancer	0.000442	0.00097	CcSEcCtD
Cyclopentolate—Hallucination—Betamethasone—hematologic cancer	0.000442	0.00097	CcSEcCtD
Cyclopentolate—Dermatitis—Cladribine—hematologic cancer	0.000442	0.000969	CcSEcCtD
Cyclopentolate—Somnolence—Carmustine—hematologic cancer	0.000441	0.000967	CcSEcCtD
Cyclopentolate—Pruritus—Lenalidomide—hematologic cancer	0.00044	0.000966	CcSEcCtD
Cyclopentolate—Ataxia—Methotrexate—hematologic cancer	0.00044	0.000964	CcSEcCtD
Cyclopentolate—Vision blurred—Prednisolone—hematologic cancer	0.000437	0.000958	CcSEcCtD
Cyclopentolate—Somnolence—Alitretinoin—hematologic cancer	0.000437	0.000958	CcSEcCtD
Cyclopentolate—Somnolence—Ifosfamide—hematologic cancer	0.000432	0.000947	CcSEcCtD
Cyclopentolate—Vertigo—Etoposide—hematologic cancer	0.000422	0.000926	CcSEcCtD
Cyclopentolate—Vertigo—Prednisolone—hematologic cancer	0.000416	0.000914	CcSEcCtD
Cyclopentolate—Ataxia—Epirubicin—hematologic cancer	0.000411	0.000902	CcSEcCtD
Cyclopentolate—Somnolence—Mitoxantrone—hematologic cancer	0.00041	0.000899	CcSEcCtD
Cyclopentolate—Somnolence—Irinotecan—hematologic cancer	0.00041	0.000899	CcSEcCtD
Cyclopentolate—Tachycardia—Cisplatin—hematologic cancer	0.000409	0.000896	CcSEcCtD
Cyclopentolate—Convulsion—Etoposide—hematologic cancer	0.000407	0.000893	CcSEcCtD
Cyclopentolate—Diphenhydramine—SLC22A1—hematologic cancer	0.000405	0.205	CrCbGaD
Cyclopentolate—Pruritus—Bortezomib—hematologic cancer	0.000405	0.000889	CcSEcCtD
Cyclopentolate—Rash—Melphalan—hematologic cancer	0.000404	0.000885	CcSEcCtD
Cyclopentolate—Dermatitis—Melphalan—hematologic cancer	0.000403	0.000884	CcSEcCtD
Cyclopentolate—Pruritus—Bleomycin—hematologic cancer	0.000402	0.000882	CcSEcCtD
Cyclopentolate—Convulsion—Prednisolone—hematologic cancer	0.000402	0.000881	CcSEcCtD
Cyclopentolate—Somnolence—Gemcitabine—hematologic cancer	0.000399	0.000876	CcSEcCtD
Cyclopentolate—Venlafaxine—ABCB1—hematologic cancer	0.000399	0.202	CrCbGaD
Cyclopentolate—Pruritus—Vinorelbine—hematologic cancer	0.000396	0.000868	CcSEcCtD
Cyclopentolate—Rash—Lenalidomide—hematologic cancer	0.000392	0.000861	CcSEcCtD
Cyclopentolate—Dermatitis—Lenalidomide—hematologic cancer	0.000392	0.00086	CcSEcCtD
Cyclopentolate—Rash—Hydroxyurea—hematologic cancer	0.000387	0.000849	CcSEcCtD
Cyclopentolate—Dermatitis—Hydroxyurea—hematologic cancer	0.000387	0.000848	CcSEcCtD
Cyclopentolate—Hallucination—Prednisone—hematologic cancer	0.000385	0.000845	CcSEcCtD
Cyclopentolate—Vertigo—Triamcinolone—hematologic cancer	0.000383	0.00084	CcSEcCtD
Cyclopentolate—Abdominal distension—Epirubicin—hematologic cancer	0.000381	0.000835	CcSEcCtD
Cyclopentolate—Ataxia—Doxorubicin—hematologic cancer	0.000381	0.000835	CcSEcCtD
Cyclopentolate—Pruritus—Thiotepa—hematologic cancer	0.000378	0.000829	CcSEcCtD
Cyclopentolate—Tachycardia—Etoposide—hematologic cancer	0.000374	0.000821	CcSEcCtD
Cyclopentolate—Convulsion—Triamcinolone—hematologic cancer	0.000369	0.00081	CcSEcCtD
Cyclopentolate—Tachycardia—Prednisolone—hematologic cancer	0.000369	0.00081	CcSEcCtD
Cyclopentolate—Pruritus—Thalidomide—hematologic cancer	0.000365	0.000802	CcSEcCtD
Cyclopentolate—Rash—Bortezomib—hematologic cancer	0.000361	0.000792	CcSEcCtD
Cyclopentolate—Dermatitis—Bortezomib—hematologic cancer	0.000361	0.000791	CcSEcCtD
Cyclopentolate—Drowsiness—Methotrexate—hematologic cancer	0.00036	0.00079	CcSEcCtD
Cyclopentolate—Flushing—Prednisone—hematologic cancer	0.000359	0.000788	CcSEcCtD
Cyclopentolate—Rash—Bleomycin—hematologic cancer	0.000358	0.000786	CcSEcCtD
Cyclopentolate—Dermatitis—Bleomycin—hematologic cancer	0.000358	0.000785	CcSEcCtD
Cyclopentolate—Dry mouth—Triamcinolone—hematologic cancer	0.000355	0.000779	CcSEcCtD
Cyclopentolate—Rash—Vinorelbine—hematologic cancer	0.000353	0.000773	CcSEcCtD
Cyclopentolate—Dermatitis—Vinorelbine—hematologic cancer	0.000352	0.000773	CcSEcCtD
Cyclopentolate—Abdominal distension—Doxorubicin—hematologic cancer	0.000352	0.000773	CcSEcCtD
Cyclopentolate—Conjunctivitis—Methotrexate—hematologic cancer	0.00035	0.000768	CcSEcCtD
Cyclopentolate—Pruritus—Alitretinoin—hematologic cancer	0.000348	0.000763	CcSEcCtD
Cyclopentolate—Vertigo—Betamethasone—hematologic cancer	0.000348	0.000762	CcSEcCtD
Cyclopentolate—Vertigo—Dexamethasone—hematologic cancer	0.000348	0.000762	CcSEcCtD
Cyclopentolate—Pruritus—Ifosfamide—hematologic cancer	0.000344	0.000754	CcSEcCtD
Cyclopentolate—Somnolence—Etoposide—hematologic cancer	0.000341	0.000748	CcSEcCtD
Cyclopentolate—Tachycardia—Triamcinolone—hematologic cancer	0.00034	0.000745	CcSEcCtD
Cyclopentolate—Drowsiness—Epirubicin—hematologic cancer	0.000337	0.00074	CcSEcCtD
Cyclopentolate—Rash—Thiotepa—hematologic cancer	0.000337	0.000739	CcSEcCtD
Cyclopentolate—Dermatitis—Thiotepa—hematologic cancer	0.000336	0.000738	CcSEcCtD
Cyclopentolate—Convulsion—Dexamethasone—hematologic cancer	0.000335	0.000735	CcSEcCtD
Cyclopentolate—Convulsion—Betamethasone—hematologic cancer	0.000335	0.000735	CcSEcCtD
Cyclopentolate—Conjunctivitis—Epirubicin—hematologic cancer	0.000328	0.000719	CcSEcCtD
Cyclopentolate—Rash—Thalidomide—hematologic cancer	0.000326	0.000714	CcSEcCtD
Cyclopentolate—Dermatitis—Thalidomide—hematologic cancer	0.000325	0.000714	CcSEcCtD
Cyclopentolate—Pruritus—Gemcitabine—hematologic cancer	0.000318	0.000697	CcSEcCtD
Cyclopentolate—Vision blurred—Prednisone—hematologic cancer	0.000317	0.000696	CcSEcCtD
Cyclopentolate—Rash—Carmustine—hematologic cancer	0.000313	0.000686	CcSEcCtD
Cyclopentolate—Dermatitis—Carmustine—hematologic cancer	0.000312	0.000685	CcSEcCtD
Cyclopentolate—Drowsiness—Doxorubicin—hematologic cancer	0.000312	0.000684	CcSEcCtD
Cyclopentolate—Rash—Alitretinoin—hematologic cancer	0.00031	0.00068	CcSEcCtD
Cyclopentolate—Agitation—Prednisone—hematologic cancer	0.00031	0.000679	CcSEcCtD
Cyclopentolate—Dermatitis—Alitretinoin—hematologic cancer	0.00031	0.000679	CcSEcCtD
Cyclopentolate—Tachycardia—Dexamethasone—hematologic cancer	0.000308	0.000676	CcSEcCtD
Cyclopentolate—Tachycardia—Betamethasone—hematologic cancer	0.000308	0.000676	CcSEcCtD
Cyclopentolate—Rash—Ifosfamide—hematologic cancer	0.000306	0.000672	CcSEcCtD
Cyclopentolate—Dermatitis—Ifosfamide—hematologic cancer	0.000306	0.000671	CcSEcCtD
Cyclopentolate—Conjunctivitis—Doxorubicin—hematologic cancer	0.000303	0.000665	CcSEcCtD
Cyclopentolate—Vertigo—Prednisone—hematologic cancer	0.000303	0.000664	CcSEcCtD
Cyclopentolate—Rash—Vincristine—hematologic cancer	0.000299	0.000655	CcSEcCtD
Cyclopentolate—Dermatitis—Vincristine—hematologic cancer	0.000298	0.000654	CcSEcCtD
Cyclopentolate—Convulsion—Prednisone—hematologic cancer	0.000292	0.00064	CcSEcCtD
Cyclopentolate—Rash—Irinotecan—hematologic cancer	0.000291	0.000638	CcSEcCtD
Cyclopentolate—Rash—Mitoxantrone—hematologic cancer	0.000291	0.000638	CcSEcCtD
Cyclopentolate—Dermatitis—Irinotecan—hematologic cancer	0.000291	0.000637	CcSEcCtD
Cyclopentolate—Dermatitis—Mitoxantrone—hematologic cancer	0.000291	0.000637	CcSEcCtD
Cyclopentolate—Rash—Gemcitabine—hematologic cancer	0.000283	0.000621	CcSEcCtD
Cyclopentolate—Dermatitis—Gemcitabine—hematologic cancer	0.000283	0.000621	CcSEcCtD
Cyclopentolate—Flushing—Epirubicin—hematologic cancer	0.000281	0.000616	CcSEcCtD
Cyclopentolate—Pruritus—Etoposide—hematologic cancer	0.000271	0.000595	CcSEcCtD
Cyclopentolate—Tachycardia—Prednisone—hematologic cancer	0.000268	0.000589	CcSEcCtD
Cyclopentolate—Vision blurred—Methotrexate—hematologic cancer	0.000265	0.000582	CcSEcCtD
Cyclopentolate—Rash—Cisplatin—hematologic cancer	0.000264	0.000579	CcSEcCtD
Cyclopentolate—Dermatitis—Cisplatin—hematologic cancer	0.000264	0.000579	CcSEcCtD
Cyclopentolate—Flushing—Doxorubicin—hematologic cancer	0.00026	0.00057	CcSEcCtD
Cyclopentolate—Vertigo—Methotrexate—hematologic cancer	0.000253	0.000555	CcSEcCtD
Cyclopentolate—Vision blurred—Epirubicin—hematologic cancer	0.000248	0.000545	CcSEcCtD
Cyclopentolate—Pruritus—Triamcinolone—hematologic cancer	0.000246	0.00054	CcSEcCtD
Cyclopentolate—Convulsion—Methotrexate—hematologic cancer	0.000244	0.000535	CcSEcCtD
Cyclopentolate—Agitation—Epirubicin—hematologic cancer	0.000242	0.000531	CcSEcCtD
Cyclopentolate—Rash—Etoposide—hematologic cancer	0.000242	0.000531	CcSEcCtD
Cyclopentolate—Dermatitis—Etoposide—hematologic cancer	0.000242	0.00053	CcSEcCtD
Cyclopentolate—Rash—Prednisolone—hematologic cancer	0.000239	0.000523	CcSEcCtD
Cyclopentolate—Dermatitis—Prednisolone—hematologic cancer	0.000238	0.000523	CcSEcCtD
Cyclopentolate—Vertigo—Epirubicin—hematologic cancer	0.000237	0.000519	CcSEcCtD
Cyclopentolate—Vision blurred—Doxorubicin—hematologic cancer	0.00023	0.000504	CcSEcCtD
Cyclopentolate—Convulsion—Epirubicin—hematologic cancer	0.000228	0.000501	CcSEcCtD
Cyclopentolate—Agitation—Doxorubicin—hematologic cancer	0.000224	0.000491	CcSEcCtD
Cyclopentolate—Pruritus—Betamethasone—hematologic cancer	0.000223	0.00049	CcSEcCtD
Cyclopentolate—Pruritus—Dexamethasone—hematologic cancer	0.000223	0.00049	CcSEcCtD
Cyclopentolate—Rash—Triamcinolone—hematologic cancer	0.000219	0.000481	CcSEcCtD
Cyclopentolate—Dry mouth—Epirubicin—hematologic cancer	0.000219	0.000481	CcSEcCtD
Cyclopentolate—Dermatitis—Triamcinolone—hematologic cancer	0.000219	0.000481	CcSEcCtD
Cyclopentolate—Vertigo—Doxorubicin—hematologic cancer	0.000219	0.00048	CcSEcCtD
Cyclopentolate—Pethidine—ALB—hematologic cancer	0.000214	0.108	CrCbGaD
Cyclopentolate—Convulsion—Doxorubicin—hematologic cancer	0.000211	0.000463	CcSEcCtD
Cyclopentolate—Tachycardia—Epirubicin—hematologic cancer	0.00021	0.00046	CcSEcCtD
Cyclopentolate—Somnolence—Methotrexate—hematologic cancer	0.000204	0.000448	CcSEcCtD
Cyclopentolate—Dry mouth—Doxorubicin—hematologic cancer	0.000203	0.000445	CcSEcCtD
Cyclopentolate—Rash—Dexamethasone—hematologic cancer	0.000199	0.000437	CcSEcCtD
Cyclopentolate—Rash—Betamethasone—hematologic cancer	0.000199	0.000437	CcSEcCtD
Cyclopentolate—Dermatitis—Dexamethasone—hematologic cancer	0.000199	0.000436	CcSEcCtD
Cyclopentolate—Dermatitis—Betamethasone—hematologic cancer	0.000199	0.000436	CcSEcCtD
Cyclopentolate—Pruritus—Prednisone—hematologic cancer	0.000195	0.000427	CcSEcCtD
Cyclopentolate—Tachycardia—Doxorubicin—hematologic cancer	0.000194	0.000426	CcSEcCtD
Cyclopentolate—Somnolence—Epirubicin—hematologic cancer	0.000191	0.000419	CcSEcCtD
Cyclopentolate—Somnolence—Doxorubicin—hematologic cancer	0.000177	0.000388	CcSEcCtD
Cyclopentolate—Rash—Prednisone—hematologic cancer	0.000173	0.00038	CcSEcCtD
Cyclopentolate—Dermatitis—Prednisone—hematologic cancer	0.000173	0.00038	CcSEcCtD
Cyclopentolate—Pruritus—Methotrexate—hematologic cancer	0.000163	0.000357	CcSEcCtD
Cyclopentolate—Pruritus—Epirubicin—hematologic cancer	0.000152	0.000334	CcSEcCtD
Cyclopentolate—Rash—Methotrexate—hematologic cancer	0.000145	0.000318	CcSEcCtD
Cyclopentolate—Dermatitis—Methotrexate—hematologic cancer	0.000145	0.000317	CcSEcCtD
Cyclopentolate—Pruritus—Doxorubicin—hematologic cancer	0.000141	0.000309	CcSEcCtD
Cyclopentolate—Rash—Epirubicin—hematologic cancer	0.000136	0.000297	CcSEcCtD
Cyclopentolate—Dermatitis—Epirubicin—hematologic cancer	0.000135	0.000297	CcSEcCtD
Cyclopentolate—Rash—Doxorubicin—hematologic cancer	0.000125	0.000275	CcSEcCtD
Cyclopentolate—Dermatitis—Doxorubicin—hematologic cancer	0.000125	0.000275	CcSEcCtD
Cyclopentolate—CHRM3—Signaling Pathways—CCL3—hematologic cancer	2.93e-05	0.00035	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—HSPB1—hematologic cancer	2.93e-05	0.00035	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—EIF4EBP1—hematologic cancer	2.93e-05	0.00035	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PTHLH—hematologic cancer	2.91e-05	0.000347	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—SDC1—hematologic cancer	2.91e-05	0.000347	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PTHLH—hematologic cancer	2.9e-05	0.000346	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—SDC1—hematologic cancer	2.9e-05	0.000346	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—IL2RA—hematologic cancer	2.86e-05	0.000341	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—IL2RA—hematologic cancer	2.85e-05	0.00034	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PTGER4—hematologic cancer	2.83e-05	0.000338	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PTGER4—hematologic cancer	2.82e-05	0.000337	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—LCK—hematologic cancer	2.82e-05	0.000336	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—LCK—hematologic cancer	2.81e-05	0.000335	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—CYCS—hematologic cancer	2.79e-05	0.000333	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—HSP90AA1—hematologic cancer	2.77e-05	0.00033	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—H3F3A—hematologic cancer	2.76e-05	0.000329	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—H3F3A—hematologic cancer	2.75e-05	0.000328	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PRKCZ—hematologic cancer	2.68e-05	0.00032	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PRKCZ—hematologic cancer	2.67e-05	0.000319	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—PIK3CG—hematologic cancer	2.62e-05	0.000313	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—PIK3CG—hematologic cancer	2.61e-05	0.000312	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—MTHFR—hematologic cancer	2.6e-05	0.00031	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PARP1—hematologic cancer	2.59e-05	0.000309	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PARP1—hematologic cancer	2.58e-05	0.000308	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—FBXW7—hematologic cancer	2.55e-05	0.000304	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—FBXW7—hematologic cancer	2.54e-05	0.000303	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—HDAC2—hematologic cancer	2.5e-05	0.000298	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CXCR4—hematologic cancer	2.5e-05	0.000298	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—HDAC2—hematologic cancer	2.49e-05	0.000297	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CXCR4—hematologic cancer	2.49e-05	0.000297	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—GSTP1—hematologic cancer	2.46e-05	0.000293	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CBL—hematologic cancer	2.44e-05	0.000291	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CBL—hematologic cancer	2.43e-05	0.00029	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—IL3—hematologic cancer	2.41e-05	0.000288	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—IL3—hematologic cancer	2.4e-05	0.000287	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—PIK3CG—hematologic cancer	2.38e-05	0.000284	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—PIK3CG—hematologic cancer	2.37e-05	0.000283	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PTPN1—hematologic cancer	2.37e-05	0.000283	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PTPN1—hematologic cancer	2.36e-05	0.000282	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—PTPN11—hematologic cancer	2.34e-05	0.000279	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—PTPN11—hematologic cancer	2.33e-05	0.000278	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—RASGRP1—hematologic cancer	2.33e-05	0.000278	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—ABCB1—hematologic cancer	2.33e-05	0.000278	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—RASGRP1—hematologic cancer	2.32e-05	0.000277	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—HSP90AA1—hematologic cancer	2.32e-05	0.000277	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—SYK—hematologic cancer	2.32e-05	0.000277	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—HSP90AA1—hematologic cancer	2.32e-05	0.000276	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—SYK—hematologic cancer	2.32e-05	0.000276	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—PIK3CD—hematologic cancer	2.31e-05	0.000275	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—PIK3CD—hematologic cancer	2.3e-05	0.000274	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	2.29e-05	0.000273	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—CREB1—hematologic cancer	2.27e-05	0.00027	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—CREB1—hematologic cancer	2.26e-05	0.00027	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—NCOR1—hematologic cancer	2.26e-05	0.000269	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—GSTM1—hematologic cancer	2.26e-05	0.000269	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—STAT1—hematologic cancer	2.24e-05	0.000267	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—STAT1—hematologic cancer	2.23e-05	0.000266	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—CCL2—hematologic cancer	2.22e-05	0.000265	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—IL6R—hematologic cancer	2.21e-05	0.000264	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—CCL2—hematologic cancer	2.21e-05	0.000264	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—IL6R—hematologic cancer	2.2e-05	0.000263	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—PIK3CG—hematologic cancer	2.18e-05	0.00026	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—PIK3R1—hematologic cancer	2.18e-05	0.00026	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—PIK3R1—hematologic cancer	2.17e-05	0.000259	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—JAK2—hematologic cancer	2.12e-05	0.000252	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—JAK2—hematologic cancer	2.11e-05	0.000252	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—MAP2K1—hematologic cancer	2.11e-05	0.000251	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—MAP2K1—hematologic cancer	2.1e-05	0.000251	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—GRB2—hematologic cancer	2.1e-05	0.00025	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—PIK3CD—hematologic cancer	2.09e-05	0.00025	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PDGFA—hematologic cancer	2.09e-05	0.000249	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—GRB2—hematologic cancer	2.09e-05	0.000249	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—PIK3CD—hematologic cancer	2.09e-05	0.000249	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PDGFA—hematologic cancer	2.08e-05	0.000249	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—KITLG—hematologic cancer	2.06e-05	0.000246	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—KITLG—hematologic cancer	2.05e-05	0.000245	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—CREBBP—hematologic cancer	2.02e-05	0.000241	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—STAT5A—hematologic cancer	2.01e-05	0.00024	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—PIK3CB—hematologic cancer	2.01e-05	0.00024	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—STAT5A—hematologic cancer	2.01e-05	0.00024	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—PIK3CB—hematologic cancer	2e-05	0.000239	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CDKN2B—hematologic cancer	2e-05	0.000238	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—MTHFR—hematologic cancer	2e-05	0.000238	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CDKN2B—hematologic cancer	1.99e-05	0.000238	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—PIK3R1—hematologic cancer	1.98e-05	0.000236	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—PIK3R1—hematologic cancer	1.97e-05	0.000235	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CD86—hematologic cancer	1.93e-05	0.00023	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CD86—hematologic cancer	1.93e-05	0.00023	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—JAK2—hematologic cancer	1.92e-05	0.000229	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—PIK3CD—hematologic cancer	1.92e-05	0.000229	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—JAK2—hematologic cancer	1.91e-05	0.000228	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—HES1—hematologic cancer	1.91e-05	0.000227	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—HES1—hematologic cancer	1.9e-05	0.000227	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—NCOR1—hematologic cancer	1.89e-05	0.000226	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—ALB—hematologic cancer	1.89e-05	0.000226	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—NCOR1—hematologic cancer	1.89e-05	0.000225	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CSF2—hematologic cancer	1.87e-05	0.000223	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—FGF1—hematologic cancer	1.87e-05	0.000223	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CSF2—hematologic cancer	1.87e-05	0.000223	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—FGF1—hematologic cancer	1.87e-05	0.000223	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—FOXO1—hematologic cancer	1.85e-05	0.00022	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—IL2—hematologic cancer	1.85e-05	0.00022	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PDGFRB—hematologic cancer	1.84e-05	0.00022	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—FOXO1—hematologic cancer	1.84e-05	0.00022	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—IL2—hematologic cancer	1.84e-05	0.000219	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PDGFRB—hematologic cancer	1.84e-05	0.000219	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—PIK3CB—hematologic cancer	1.82e-05	0.000218	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—PIK3CB—hematologic cancer	1.82e-05	0.000217	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PDGFRA—hematologic cancer	1.81e-05	0.000216	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—PIK3R1—hematologic cancer	1.81e-05	0.000216	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PDGFRA—hematologic cancer	1.81e-05	0.000216	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PRKCG—hematologic cancer	1.81e-05	0.000216	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—JAK1—hematologic cancer	1.81e-05	0.000216	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—JAK1—hematologic cancer	1.8e-05	0.000215	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PRKCG—hematologic cancer	1.8e-05	0.000215	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—IL2RA—hematologic cancer	1.69e-05	0.000201	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—IL2RA—hematologic cancer	1.68e-05	0.000201	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—PIK3CG—hematologic cancer	1.68e-05	0.0002	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—IL2—hematologic cancer	1.68e-05	0.0002	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—PIK3CB—hematologic cancer	1.67e-05	0.000199	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—IL2—hematologic cancer	1.67e-05	0.000199	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—TERT—hematologic cancer	1.67e-05	0.000199	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—TERT—hematologic cancer	1.66e-05	0.000199	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PDGFB—hematologic cancer	1.63e-05	0.000194	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PDGFB—hematologic cancer	1.62e-05	0.000194	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—TSC2—hematologic cancer	1.59e-05	0.00019	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—TSC2—hematologic cancer	1.59e-05	0.000189	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—CREBBP—hematologic cancer	1.55e-05	0.000185	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—FGFR3—hematologic cancer	1.53e-05	0.000183	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—FGFR3—hematologic cancer	1.53e-05	0.000182	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—MAPK14—hematologic cancer	1.52e-05	0.000181	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—MAPK14—hematologic cancer	1.51e-05	0.00018	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—ESR1—hematologic cancer	1.49e-05	0.000178	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—ESR1—hematologic cancer	1.48e-05	0.000177	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—PIK3CD—hematologic cancer	1.47e-05	0.000176	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—FN1—hematologic cancer	1.47e-05	0.000175	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—FN1—hematologic cancer	1.47e-05	0.000175	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—ALB—hematologic cancer	1.46e-05	0.000174	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—NFKBIA—hematologic cancer	1.45e-05	0.000173	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—BAD—hematologic cancer	1.45e-05	0.000173	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—NFKBIA—hematologic cancer	1.45e-05	0.000173	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—BAD—hematologic cancer	1.45e-05	0.000173	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—PTEN—hematologic cancer	1.44e-05	0.000172	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—NOTCH1—hematologic cancer	1.44e-05	0.000172	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—NOTCH1—hematologic cancer	1.43e-05	0.000171	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CD80—hematologic cancer	1.41e-05	0.000168	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PIK3CG—hematologic cancer	1.41e-05	0.000168	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—KIT—hematologic cancer	1.41e-05	0.000168	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—NRAS—hematologic cancer	1.41e-05	0.000168	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CD80—hematologic cancer	1.4e-05	0.000168	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—KIT—hematologic cancer	1.4e-05	0.000167	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PIK3CG—hematologic cancer	1.4e-05	0.000167	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—NRAS—hematologic cancer	1.4e-05	0.000167	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—PIK3R1—hematologic cancer	1.39e-05	0.000166	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PTPN11—hematologic cancer	1.38e-05	0.000165	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PTPN11—hematologic cancer	1.38e-05	0.000164	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—EP300—hematologic cancer	1.38e-05	0.000164	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—MAPK3—hematologic cancer	1.35e-05	0.000161	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—MAPK3—hematologic cancer	1.34e-05	0.00016	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CREB1—hematologic cancer	1.34e-05	0.00016	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CREB1—hematologic cancer	1.33e-05	0.000159	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—BRAF—hematologic cancer	1.32e-05	0.000158	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—BRAF—hematologic cancer	1.32e-05	0.000157	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CCL2—hematologic cancer	1.31e-05	0.000156	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—IL6R—hematologic cancer	1.31e-05	0.000156	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CCL2—hematologic cancer	1.31e-05	0.000156	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CREBBP—hematologic cancer	1.3e-05	0.000156	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—IL6R—hematologic cancer	1.3e-05	0.000155	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CREBBP—hematologic cancer	1.3e-05	0.000155	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—PIK3CB—hematologic cancer	1.28e-05	0.000153	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—MAP2K1—hematologic cancer	1.24e-05	0.000149	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—MAP2K1—hematologic cancer	1.24e-05	0.000148	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PIK3CD—hematologic cancer	1.24e-05	0.000148	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PIK3CD—hematologic cancer	1.23e-05	0.000147	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—PIK3CA—hematologic cancer	1.22e-05	0.000146	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—PIK3CA—hematologic cancer	1.22e-05	0.000146	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—KRAS—hematologic cancer	1.21e-05	0.000144	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—KRAS—hematologic cancer	1.21e-05	0.000144	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—FGF2—hematologic cancer	1.18e-05	0.000141	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—FGF2—hematologic cancer	1.18e-05	0.000141	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PIK3R1—hematologic cancer	1.17e-05	0.000139	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PIK3R1—hematologic cancer	1.16e-05	0.000139	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—JAK2—hematologic cancer	1.13e-05	0.000135	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—JAK2—hematologic cancer	1.13e-05	0.000135	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—PIK3CA—hematologic cancer	1.11e-05	0.000133	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—PTEN—hematologic cancer	1.11e-05	0.000132	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—PIK3CA—hematologic cancer	1.11e-05	0.000132	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—MDM2—hematologic cancer	1.11e-05	0.000132	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—MDM2—hematologic cancer	1.1e-05	0.000132	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—MTOR—hematologic cancer	1.08e-05	0.000129	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PIK3CB—hematologic cancer	1.08e-05	0.000129	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—MTOR—hematologic cancer	1.07e-05	0.000128	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PIK3CB—hematologic cancer	1.07e-05	0.000128	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—EP300—hematologic cancer	1.06e-05	0.000126	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—HRAS—hematologic cancer	1.03e-05	0.000123	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—HRAS—hematologic cancer	1.03e-05	0.000122	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—PIK3CA—hematologic cancer	1.02e-05	0.000122	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CDKN1B—hematologic cancer	1.01e-05	0.000121	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CDKN1B—hematologic cancer	1.01e-05	0.00012	CbGpPWpGaD
Cyclopentolate—CHRM1—GPCR downstream signaling—AKT1—hematologic cancer	1e-05	0.000119	CbGpPWpGaD
Cyclopentolate—CHRM3—GPCR downstream signaling—AKT1—hematologic cancer	9.97e-06	0.000119	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CASP3—hematologic cancer	9.91e-06	0.000118	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—IL2—hematologic cancer	9.9e-06	0.000118	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CASP3—hematologic cancer	9.88e-06	0.000118	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—IL2—hematologic cancer	9.87e-06	0.000118	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—IL6—hematologic cancer	9.85e-06	0.000118	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—IL6—hematologic cancer	9.82e-06	0.000117	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CCND1—hematologic cancer	9.65e-06	0.000115	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—JUN—hematologic cancer	9.63e-06	0.000115	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CCND1—hematologic cancer	9.62e-06	0.000115	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—JUN—hematologic cancer	9.6e-06	0.000115	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—CDKN1A—hematologic cancer	9.33e-06	0.000111	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PTEN—hematologic cancer	9.31e-06	0.000111	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—CDKN1A—hematologic cancer	9.31e-06	0.000111	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PTEN—hematologic cancer	9.28e-06	0.000111	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—MAPK8—hematologic cancer	9.11e-06	0.000109	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling by GPCR—AKT1—hematologic cancer	9.09e-06	0.000108	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—MAPK8—hematologic cancer	9.08e-06	0.000108	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling by GPCR—AKT1—hematologic cancer	9.06e-06	0.000108	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—EP300—hematologic cancer	8.88e-06	0.000106	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—EP300—hematologic cancer	8.85e-06	0.000106	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—SRC—hematologic cancer	8.64e-06	0.000103	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—SRC—hematologic cancer	8.61e-06	0.000103	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—VEGFA—hematologic cancer	8.41e-06	0.0001	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—VEGFA—hematologic cancer	8.39e-06	0.0001	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—STAT3—hematologic cancer	8.33e-06	9.94e-05	CbGpPWpGaD
Cyclopentolate—BCHE—Metabolism—AKT1—hematologic cancer	8.32e-06	9.93e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—NRAS—hematologic cancer	8.31e-06	9.91e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—STAT3—hematologic cancer	8.3e-06	9.91e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—NRAS—hematologic cancer	8.28e-06	9.88e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—MAPK3—hematologic cancer	7.96e-06	9.49e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—MAPK3—hematologic cancer	7.93e-06	9.46e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—PIK3CA—hematologic cancer	7.83e-06	9.34e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—MYC—hematologic cancer	7.74e-06	9.23e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—TGFB1—hematologic cancer	7.72e-06	9.21e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—MYC—hematologic cancer	7.72e-06	9.2e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—TGFB1—hematologic cancer	7.7e-06	9.18e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—KRAS—hematologic cancer	7.15e-06	8.53e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—KRAS—hematologic cancer	7.13e-06	8.5e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—PIK3CA—hematologic cancer	6.57e-06	7.84e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—PIK3CA—hematologic cancer	6.55e-06	7.81e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Metabolism—AKT1—hematologic cancer	6.4e-06	7.63e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—TP53—hematologic cancer	6.36e-06	7.58e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—TP53—hematologic cancer	6.34e-06	7.56e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—HRAS—hematologic cancer	6.08e-06	7.25e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—HRAS—hematologic cancer	6.06e-06	7.23e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—IL6—hematologic cancer	5.82e-06	6.94e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—IL6—hematologic cancer	5.8e-06	6.92e-05	CbGpPWpGaD
Cyclopentolate—CHRM1—Signaling Pathways—AKT1—hematologic cancer	5.37e-06	6.4e-05	CbGpPWpGaD
Cyclopentolate—CHRM3—Signaling Pathways—AKT1—hematologic cancer	5.35e-06	6.38e-05	CbGpPWpGaD
